bosentan anhydrous has been researched along with Sclerosis, Systemic in 164 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 75 (45.73) | 29.6817 |
2010's | 80 (48.78) | 24.3611 |
2020's | 9 (5.49) | 2.80 |
Authors | Studies |
---|---|
Isomoto, H; Kimura, R; Sugihara, T; Sugita, K; Yamamoto, O | 1 |
Endo, Y; Ishikawa, M; Motegi, SI; Sekiguchi, A; Uchiyama, A; Yamazaki, S | 1 |
Allanore, Y; Alunno, A; Baron, M; Campochiaro, C; Chung, L; Denton, CP; Distler, O; Frech, T; Furst, DE; Giuggioli, D; Hughes, M; Khanna, D; Krieg, T; Kuwana, M; Maltez, N; Matucci-Cerinic, M; Moinzadeh, P; Pope, J; Ross, L; Schoones, JW; Suliman, YA | 1 |
Amiya, E; Asano, Y; Hatano, M; Komuro, I; Kubota, K; Maki, H; Minatsuki, S; Morita, H; Sato, S; Yoshizaki, A | 1 |
Abdulle, AE; Mulder, DJ; van Roon, AM | 1 |
Berry-Cabán, CS; Black, L; De Blasio, DC; Huh, J; Tracy, CL | 1 |
Casademont, J; Castellví, I; Corominas, H; Fonollosa, V; Sarmiento, M; Simeón, CP | 1 |
Ju, JH; Kim, BY; Kim, HS; Kim, SH; Kim, YS; Lee, KA; Park, S; Son, CN | 1 |
Fontaine, C; Jaquinandi, V; Mahe, G; Omarjee, L | 1 |
Abuowda, Y; Almeida, RS; Matos-Costa, J; Oliveira, AA; Pego, P; Santos, C | 1 |
Cutolo, M; Paolino, S; Pizzorni, C; Ruaro, B; Sulli, A | 1 |
Botella, A; Moniz, P; Rei, D; Rodrigues, J | 1 |
Abignano, G; Allanore, Y; Avouac, J; Bellando-Randone, S; Blagojevic, J; Cometi, L; Czirják, L; Del Galdo, F; Denton, CP; Distler, O; Frerix, M; Guiducci, S; Huscher, D; Jaeger, VK; Lóránd, V; Matucci-Cerinic, M; Maurer, B; Müller-Ladner, U; Nihtyanova, S; Riemekasten, G; Siegert, E; Tarner, IH; Vettori, S; Walker, UA | 1 |
Asano, Y; Fukui, Y; Hirabayashi, M; Miura, S; Miyagawa, T; Nakamura, K; Saigusa, R; Sato, S; Yamashita, T; Yoshizaki, A | 1 |
Gøransson, LG; Norheim, KB; Vikse, J | 1 |
Abignano, G; Allanore, Y; Avouac, J; Bellando-Randone, S; Blagojevic, J; Bruni, C; Cometi, L; Czirják, L; Del Galdo, F; Denton, CP; Distler, O; Frerix, M; Guiducci, S; Huscher, D; Jaeger, VK; Lóránd, V; Matucci-Cerinic, M; Maurer, B; Moggi-Pignone, A; Müller-Ladner, U; Nihtyanova, S; Riemekasten, G; Siegert, E; Tarner, IH; Vettori, S; Walker, UA | 1 |
Autenrieth, J; Bert, C; Riemekasten, G; Worm, M | 1 |
Burns, A; Chakravarty, K; Denton, CP; Khan, K; Ong, VH; Penn, H; Quillinan, N | 1 |
Deray, G; Izzedine, H; Rouvier, P | 1 |
Catarsi, E; Doveri, M; Tavoni, A | 1 |
Belperio, JA; Fishbein, MC; Lynch, JP; Saggar, R | 1 |
Aoyagi, K; Kawakami, A; Kawashiri, SY; Terada, K; Ueki, Y; Yamasaki, S | 1 |
Romaniello, A; Rosato, E; Salsano, F; Viola, G | 1 |
Bölke, E; Buhren, BA; Gerber, PA; Hetzer, S; Homey, B; Kammers, K; Meller, S; Schrumpf, H | 1 |
Denton, CP; Ngcozana, T; Ong, V | 1 |
Cimmino, M; Cutolo, M; Paolino, S; Pizzorni, C; Ravera, F; Ruaro, B; Seriolo, B; Smith, V; Sulli, A; Zampogna, G | 1 |
Akamata, K; Aozasa, N; Asano, Y; Ichimura, Y; Noda, S; Sato, S; Takahashi, T; Taniguchi, T; Toyama, T | 1 |
Agard, C; Bérezné, A; Carpentier, PH; Chatelus, E; Clerson, P; Diot, E; Gressin, V; Hachulla, E; Jego, P; Lok, C; Mouthon, L; Quéré, I; Sibilia, J; Sparsa, A; Van Kien, AK | 1 |
Glukhova, SI; Iudkina, NN; Kurmukov, IA; Nasonov, EL; Nikolaeva, EV; Volkov, AV | 1 |
Corkill, MM; Ghosh, SK; Hart, HH; Ng, KP | 1 |
Bloemsaat-Minekus, JP; Meijs, J; Vonk, MC; Voskuyl, AE | 1 |
Belz, D; Hunzelmann, N; Moinzadeh, P | 1 |
Alessandri, E; Brizzolara, R; Cutolo, M; Montagna, P; Pizzorni, C; Smith, V; Soldano, S; Sulli, A; Tavilla, PP; Villaggio, B | 1 |
Akamata, K; Asano, Y; Ichimura, Y; Noda, S; Sato, S; Takahashi, T; Taniguchi, T; Toyama, T; Trojanowska, M; Yamashita, T | 1 |
Kinoshita, H; Yoshifuji, H | 1 |
Glukhova, SI; Kurmukov, IA; Nikolaeva, EV; Volkov, AV; Yudkina, NN | 1 |
Asano, Y | 1 |
Alessandro, B; Andrea, O; Antonio, P; Claudio, L; Daniela, R; Elisa, T; Federico, C; Giacomo, M; Giuseppe, A; Giuseppe, P; Mariaelisa, R; Marzia, D; Ruggero, B | 1 |
di Serio, F; Iannone, F; Lapadula, G; Nivuori, M; Praino, E; Rotondo, C | 1 |
Sharabi, I; Tanay, A; Zandman-Goddard, G | 1 |
Asano, Y; Ichimura, Y; Miyagaki, T; Saigusa, R; Sato, S; Sugaya, M; Takahashi, T; Taniguchi, T; Toyama, T; Yamashita, T; Yoshizaki, A | 1 |
Bellando-Randone, S; Blagojevic, J; Bruni, C; Cometi, L; De Paulis, A; Guiducci, S; Lepri, G; Matucci-Cerinic, M; Radicati, A | 1 |
Bernal, M; De Cata, A; De Cosmo, S; Inglese, M; Mazzoccoli, G; Molinaro, F; Rubino, R | 1 |
Cannarile, F; Cestelli, V; Ferri, C; Giuggioli, D; Manfredi, A; Praino, E; Sebastiani, M | 1 |
Asano, Y; Endo, H; Hamaguchi, Y; Ihn, H; Kawaguchi, Y; Kuwana, M; Motegi, SI; Sumida, T; Takehara, K; Tanaka, S | 1 |
Beissert, S; Distler, JH; Kreuter, A; Müller-Ladner, U; Riemekasten, G | 1 |
Amoroso, D; Barbano, B; Di Paolo, M; Gigante, A; Palange, P; Romaniello, A; Rosato, E; Tallerini, G | 1 |
Chirico, C; Corallo, C; Cutolo, M; Giordano, N; Kahaleh, B; Montella, A; Nuti, R; Pecetti, G; Soldano, S | 1 |
Cutolo, M; Paolino, S; Pizzorni, C; Ruaro, B; Smith, V; Sulli, A; Trombetta, AC | 1 |
Agard, C; Bérezné, A; Carpentier, PH; Clerson, P; Diot, E; Duval-Modeste, AB; Gressin, V; Hachulla, E; Jego, P; Lok, C; Mouthon, L; Puzenat, E; Richard, MA; Sparsa, A; Van Kien, AK | 1 |
Blaise, S; Cracowski, JL; Forli, A; Imbert, B; Roustit, M | 1 |
Heresi, GA; Minai, OA | 1 |
Coghlan, G; Kabunga, P | 1 |
Langevitz, P; Shalev, L; Zandman-Goddard, G | 1 |
Dimitroula, H; Dimitroulas, T; Giannakoulas, G; Karvounis, H; Settas, L | 1 |
Silver, RM | 1 |
Matucci-Cerinic, M; Seibold, JR | 1 |
Ferreira, ME; Scheinberg, MA | 1 |
Funauchi, M; Hino, S; Kinoshita, K; Kishimoto, K; Nagare, Y; Shimazu, H; Yano, T | 1 |
Favre, J; Henry, JP; Lallemand, F; Marie, I; Richard, V; Solans, V; Thuillez, C | 1 |
Agard, C; Haloun, A; Hamidou, MA | 1 |
Champion, HC; Girgis, RE; Hassoun, PM; Hummers, LK; Mathai, SC; Wigley, FM; Zaiman, A | 1 |
Caruso, C; Giovannetti, A; Pierdominici, M; Romano, A; Rosato, E; Salsano, F | 1 |
Dwyer, N; Jones, G; Kilpatrick, D | 1 |
Fujimoto, M; Hamaguchi, Y; Hasegawa, M; Matsushita, T; Takehara, K | 1 |
Denton, CP; Matucci-Cerinic, M; Pope, JE; Steen, V | 1 |
Coghlan, G; Humbert, M; McLaughlin, V; Nash, P; Steen, V | 1 |
Guillevin, L | 3 |
Alamanos, Y; Argyriou, E; Botzoris, V; Drosos, AA; Tsifetaki, N; Zioga, A | 1 |
Dhillon, S | 1 |
Wimmersberger, Y; Zuercher, D | 1 |
Achouh, L; Humbert, M; Jais, X; Launay, D; Le Pavec, J; Parent, F; Savale, L; Simonneau, G; Sitbon, O; Tchérakian, C; Yaïci, A | 1 |
Bambara, LM; Biasi, D; Caramaschi, P; Mahamid, H | 1 |
Eisendle, K; Gruber, I; Hugl, B; Nguyen, VA; Reider, D; Reider, N | 1 |
Felder, G; Gensch, K; Haust, M; Kuhn, A; Ohmann, C; Ruland, V; Ruzicka, T; Verde, P; Weber, R | 1 |
Allanore, Y; Isvy, A; Kahan, A; Maury, E; Moachon, L | 1 |
Black, CM; Chadha-Boreham, H; Charef, P; Denton, CP; Emery, P; Furst, DE; Guillevin, L; Matucci Cerinic, M; Riemekasten, G; Roux, S; Rubin, LJ; Seibold, JR; Wells, A | 1 |
Bredemeier, M | 1 |
Black, CM; Carpentier, P; Denton, CP; Doyle, MK; Fessler, BJ; Furst, DE; Hellmich, B; Hsu, VM; Korn, JH; Kramer, F; Matucci-Cerinic, M; Mayes, MD; Medsger, TA; Merkel, PA; Morganti, A; Pope, JE; Seibold, JR; Sweiss, NJ; Wigley, FM | 1 |
Borghese, F; Molinaro, I; Pisarri, S; Rosato, E; Rossi, C; Salsano, F | 1 |
Pope, J; Zelenietz, C | 1 |
Aihara, K; Akaike, M; Dagvasumberel, M; Hirata, Y; Iwase, T; Koshiba, K; Kusunose, K; Matsumoto, T; Niki, T; Sata, M; Soeki, T; Sumitomo-Ueda, Y; Taketani, Y; Tomita, N; Wakatsuki, T; Yagi, S; Yamada, H; Yamaguchi, K; Yoshida, S | 1 |
Gocho, K; Homma, S; Kusano, E; Ota, H; Sugino, K; Takai, Y | 1 |
Enk, A; Hartmann, M; Hartschuh, W; Haust, M; Klein, S; Krammer, PH; Kretz, CC; Kuhn, A; Oberle, N; Ruland, V; Stumpf, C; Suri-Payer, E | 1 |
Lambova, S; Müller-Ladner, U | 1 |
Botzoris, V; Drosos, AA | 1 |
Derk, CT; Shetty, N | 1 |
Bakx, R; Dogan, K; Klemm, PL | 1 |
Aihara, K; Akaike, M; Iwase, T; Matsumoto, T; Sata, M; Sumitomo-Ueda, Y; Yagi, S; Yoshida, S | 1 |
Pope, J; Walker, KM | 1 |
Alegre Sancho, JJ; Castillo, MJ; Egurbide, MV; Fonollosa, V; Lloria, X; Roman Ivorra, JA; Simeon, CP | 1 |
Belamarich, PF; Ilowite, NT; Kenney-Riley, KM; Wahezi, DM | 1 |
Hashida, Y; Nakayama, Y; Ohta, K; Saito, T; Shimizu, M; Takehara, K; Ueno, K; Yachie, A; Yokoyama, T | 1 |
Brodmann, M; Froehlich, H; Hafner, F; Steidl, K; Thomas, G | 1 |
Hunzelmann, N; Krieg, T; Moinzadeh, P | 1 |
Akamata, K; Asano, Y; Hatano, M; Ichimura, Y; Kawashima, T; Kinugawa, K; Miyazaki, M; Noda, S; Sato, S; Sugita, M; Sumida, H; Takahashi, T; Tamaki, Z; Taniguchi, T; Tomita, M; Toyama, T; Yao, A | 1 |
Kurgyis, Z; Lang, MU; Ruzicka, T; Sárdy, M; Sick, I; Varga, R | 1 |
Furuya, Y; Kuwana, M | 1 |
Hasegawa, M; Hattori, T; Ishikawa, O; Nagai, Y; Okada, E; Tago, O | 1 |
Aberer, E; Brodmann, M; Graninger, W; Hesse, C; Kovacs, G; Kqiku, X; Maier, R; Olschewski, H; Rubin, L; Scheidl, S; Tröster, N | 1 |
Hoffmann, U; Kuhn, A; Riemekasten, G; Sunderkötter, C; Weiss, N | 1 |
Stern, PJ; Wall, LB | 1 |
Nishibu, A; Oyama, N; Sakai, E; Yamamoto, T | 1 |
Bellando Randone, S; Bruni, C; Carnesecchi, G; Guiducci, S; Iannone, F; Lapadula, G; Maresta, A; Matucci Cerinic, M | 1 |
Cutolo, M; Pizzorni, C; Smith, V; Sulli, A; Vremis, L; Zampogna, G | 1 |
Gerry Coghlan, J; Humbert, M; Khanna, D | 1 |
Celermajer, DS; Corte, TJ; Don, GW; Joseph, F | 1 |
Brizzolara, R; Cutolo, M; Ferrone, C; Montagna, P; Parodio, A; Seriolo, B; Soldano, S; Sulli, A; Villaggio, B | 1 |
Cardarelli, S; Cozzi, F; Favaro, M; Pigatto, E; Punzi, L; Riato, L; Rizzo, M; Zanatta, E | 1 |
Schachna, L; Wigley, FM | 1 |
Cabane, J; Humbert, M | 1 |
Varga, J | 2 |
Korn, JH | 1 |
Hachulla, E | 1 |
Budde, K; Dingemanse, J; Hocher, B; Liefeldt, L; Neumayer, HH; Rudolph, B; van Giersbergen, PL; Walde, T | 1 |
Coghlan, JG; Hachulla, E | 1 |
Brito-Zerón, P; Claver, G; Fernandez, S; Font, J; Julià, M; Nardi, N; Parraga, FD; Ramos-Casals, M; Risco, G | 1 |
Black, C; Carpentier, P; Chatterjee, S; Coppock, J; Denton, CP; Furst, D; Gaitonde, M; Guillevin, L; Hachulla, E; Herrick, A; Hsu, V; Korn, JH; Matucci Cerinic, M; Mayes, M; Merkel, PA; Molitor, J; Nguyen, N; Peter, HH; Pope, J; Rainisio, M; Rich, E; Seibold, JR; Simms, R | 1 |
Ahmadi-Simab, K; Gross, WL; Hellmisch, B; Lamprecht, P | 1 |
Antonaci, S; Giannelli, G; Iannone, F; Lapadula, G; Marinosci, F | 2 |
Grau, RG; Jacobs, MR; Knox, KS; Snyder, MJ; Wilkes, DS | 1 |
Girgis, RE; Hassoun, PM; Krishnan, JA; Mathai, SC; Wigley, FM | 1 |
Akram, MR; Black, CM; Coghlan, JG; Das, C; Davar, J; Denton, CP; Handler, CE; Smith, CJ; Williams, MH | 1 |
Kashour, T; Philipp, R; Sharma, S | 1 |
Joglekar, A; McCloskey, DA; Riley, DJ; Seibold, JR; Tsai, FS; Wilson, JE | 1 |
Riemekasten, G | 1 |
Dunne, J; Dutz, J; Ng, B; Shojania, K; van Eeden, S | 1 |
Cozzi, F; Favaro, M; Marotta, H; Ostuni, PA; Sfriso, P; Todesco, S | 1 |
Boullanger, N; Carpentier, P; Diot, E; Fain, O; Hachulla, E; Hatron, PY; Jego, P; Launay, D; Mouthon, L; Pasquier, E | 1 |
Chevallier, D; Hervé, F; Levesque, H; Marie, I; Muir, JF; Tillon, J | 1 |
Hasegawa, A; Ishikawa, O; Nagai, Y; Nakano, A; Nishimura, S; Yamanaka, M | 1 |
Lyseng-Williamson, KA; Oldfield, V | 1 |
Black, CM; Denton, CP; Humbert, M; Rubin, L | 1 |
Jain, M; Varga, J | 1 |
Musch, A | 1 |
McLaughlin, VV | 1 |
Ahmadi-Simab, K; Gross, WL; Hellmich, B | 1 |
Bobbo, F; Cozzi, F; Durigon, N; Iliceto, S; Marotta, H; Montisci, R; Ruscazio, M; Sfriso, P; Todesco, S | 1 |
Beretta, L; Del Papa, N; Mazzone, A; Scorza, R | 1 |
Duschek, N; Karlhofer, F; Minimair, G; Selenko-Gebauer, N; Stingl, G | 1 |
Champion, HC; Fisher, MR; Girgis, RE; Hassoun, PM; Housten-Harris, T; Mathai, SC; Zaiman, A | 1 |
Allanore, Y; Kahan, A; Legmann, P; Meune, C; Vignaux, O; Weber, S | 1 |
Herrick, AL; Moore, TL; Vail, A | 1 |
Hachulla, E; Humbert, M; Launay, D | 1 |
Chamaillard, M; Constans, J; Heliot-Hosten, I; Taïeb, A | 1 |
Hoeper, MM | 1 |
Rösener, I; Rübben, A | 1 |
Fain, O | 1 |
Fragiadaki, KG; Katsichti, P; Mavrikakis, M; Papamichael, C; Sfikakis, PP; Stamatelopoulos, KS; Stefanadis, C; Tousoulis, D | 1 |
Abraham, DJ; Black, CM; Bou-Gharios, G; Chen, Y; Dashwood, MR; Denton, CP; du Bois, RM; Howat, S; Kennedy, L; Leask, A; Pearson, JD; Renzoni, EA; Shi-Wen, X | 1 |
Bootsma, H; Hettema, ME; Kallenberg, CG; Zhang, D | 1 |
Humbert, M | 1 |
Bizzoca, R; Cinelli, M; Guiducci, S; Iannone, F; Lapadula, G; Matucci-Cerinic, M; Riccardi, MT | 1 |
Corrocher, R; Lippi, G; Lunardi, C; Montagnana, M; Prati, D; Puccetti, A; Simeoni, S; Tinazzi, E | 1 |
Dimitroula, H; Dimitroulas, T; Giannakoulas, G; Karvounis, H; Koliakos, G; Settas, L; Sfetsios, T | 1 |
Distler, JH; Distler, O; Hoeper, MM | 1 |
Beltrán Gutiérrez, J; Carmona, L; Díaz-Miguel, C; Gámir Gámir, ML; García de la Peña-Lefebvre, P; Orte Martínez, J; Rodríguez Rubio, S; Valero Expósito, M; Zea Mendoza, AC | 1 |
Antonelli-Incalzi, R; Catapano-Minotti, G; Corsonello, A; Guadalupi, G; Spani, R | 1 |
Badesch, DB; Bodin, F; Channick, RN; Frost, A; Rainisio, M; Robbins, IM; Roux, S; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
Badesch, DB; Barst, RJ; Black, CM; Frost, A; Galie, N; Keogh, A; Landzberg, M; Leconte, I; Pulido, T; Roux, S; Rubin, LJ; Simonneau, G | 1 |
24 review(s) available for bosentan anhydrous and Sclerosis, Systemic
Article | Year |
---|---|
Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review.
Topics: Adult; Bosentan; Fingers; Humans; Scleroderma, Systemic; Skin Ulcer | 2023 |
[Management of borderline pulmonary arterial hypertension associated with connective tissue diseases].
Topics: Antihypertensive Agents; Bosentan; Connective Tissue Diseases; Disease Susceptibility; Diuretics; Early Diagnosis; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Nitric Oxide Synthase Type II; Polymorphism, Genetic; Scleroderma, Systemic; Sulfonamides; Vasodilator Agents | 2014 |
Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis.
Topics: Animals; Bleomycin; Bosentan; Disease Models, Animal; Endothelial Cells; Epigenesis, Genetic; Fibroblasts; Genetic Predisposition to Disease; Humans; Macrophages; Mice; Mice, Transgenic; Proto-Oncogene Protein c-fli-1; Scleroderma, Systemic; Sulfonamides; Th17 Cells; Th2 Cells | 2015 |
Bosentan in systemic sclerosis.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2008 |
Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Thiophenes; Treatment Outcome | 2008 |
Endothelin and scleroderma lung disease.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Humans; Lung Diseases, Interstitial; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sulfonamides; Transforming Growth Factor beta; Treatment Failure | 2008 |
Digital ulcers and outcomes assessment in scleroderma.
Topics: Bosentan; Fingers; Hand Dermatoses; Humans; Iloprost; Ischemia; Scleroderma, Systemic; Severity of Illness Index; Skin Ulcer; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2008 |
[Pulmonary arterial hypertension related to systemic sclerosis in 2008].
Topics: Altitude; Antihypertensive Agents; Bosentan; Echocardiography; Endothelin Receptor Antagonists; Endothelin-1; Enzyme Inhibitors; France; Humans; Hypertension, Pulmonary; Hypoxia; Oxygen; Phosphodiesterase 5 Inhibitors; Prognosis; Scleroderma, Systemic; Sulfonamides | 2009 |
Digital ulcers: overt vascular disease in systemic sclerosis.
Topics: Antihypertensive Agents; Bosentan; Databases, Factual; Endothelium, Vascular; Fingers; Hand Dermatoses; Humans; Raynaud Disease; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2009 |
Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Echocardiography; Epoprostenol; Exercise Tolerance; Humans; Hypertension, Pulmonary; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones | 2009 |
Vasculopathy and pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Churg-Strauss Syndrome; Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Scleroderma, Systemic; Sjogren's Syndrome; Sulfonamides; Vasculitis | 2009 |
Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis.
Topics: Bosentan; Drug Interactions; Endothelin A Receptor Antagonists; Endothelium, Vascular; Fingers; Humans; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome | 2009 |
Differences in disability as measured by the Health Assessment Questionnaire between patients with and without digital ulcers in systemic sclerosis: a post hoc analysis of pooled data from two randomised controlled trials in digital ulcers using bosentan.
Topics: Antihypertensive Agents; Bosentan; Disability Evaluation; Fingers; Hand Dermatoses; Humans; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2010 |
Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis.
Topics: Bosentan; Calcium Channel Blockers; Cardiovascular Agents; Endothelin Receptor Antagonists; Enzyme Inhibitors; Fingers; Humans; Phosphodiesterase 5 Inhibitors; Prostaglandins I; Raynaud Disease; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Vasodilator Agents | 2011 |
Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelins; Familial Primary Pulmonary Hypertension; Fibrosis; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Thiophenes; Treatment Outcome | 2011 |
[Management of digital ulcers in patients with systemic sclerosis].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Iloprost; Ischemia; Male; Raynaud Disease; Risk Factors; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Vasodilator Agents | 2012 |
Early detection and management of pulmonary arterial hypertension.
Topics: Anemia, Sickle Cell; Antihypertensive Agents; Bosentan; Early Diagnosis; Echocardiography, Doppler; Exercise Test; Humans; Hypertension, Pulmonary; Mass Screening; Natriuretic Peptide, Brain; Peptide Fragments; Piperazines; Practice Guidelines as Topic; Purines; Respiratory Function Tests; Risk Factors; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2012 |
Targeting mediators of vascular injury in scleroderma.
Topics: Antihypertensive Agents; Biomarkers; Bosentan; Clinical Trials as Topic; Endothelin-1; Endothelium, Vascular; Epoprostenol; Humans; Hypertension, Pulmonary; Muscle, Smooth, Vascular; Reactive Oxygen Species; Scleroderma, Systemic; Sulfonamides | 2002 |
[Treatment of pulmonary arterial hypertension associated to systemic sclerosis].
Topics: Antihypertensive Agents; Bosentan; Calcium; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Scleroderma, Systemic; Sulfonamides | 2004 |
A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelins; Humans; Hypertension, Pulmonary; Scleroderma, Systemic; Sulfonamides | 2004 |
Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis.
Topics: Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Receptors, Endothelin; Scleroderma, Systemic; Severity of Illness Index; Sulfonamides | 2006 |
Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers.
Topics: Animals; Bosentan; Drug Tolerance; Humans; Hypertension; Pulmonary Fibrosis; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2006 |
[Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Heart Failure; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sulfonamides | 2006 |
[Pulmonary arterial hypertension and systemic sclerosis].
Topics: Algorithms; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Cohort Studies; Echocardiography, Doppler; Epoprostenol; European Union; Humans; Hypertension, Pulmonary; Iloprost; Infusions, Intravenous; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prevalence; Prognosis; Purines; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Time Factors; Vasodilator Agents; World Health Organization | 2006 |
29 trial(s) available for bosentan anhydrous and Sclerosis, Systemic
Article | Year |
---|---|
Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey.
Topics: Adult; Bosentan; Calcium Channel Blockers; Drug Therapy, Combination; European Union; Female; Fingers; Humans; Iloprost; Male; Middle Aged; Prospective Studies; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Surveys and Questionnaires | 2019 |
Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study.
Topics: Adult; Aged; Bosentan; Drug Therapy, Combination; Europe; Female; Fingers; Humans; Iloprost; Male; Middle Aged; Prospective Studies; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Treatment Outcome; Vasodilator Agents; Wound Healing | 2020 |
Influence of bosentan on fingertip rewarming in patients with systemic sclerosis.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Female; Fingers; Humans; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Skin; Skin Temperature; Sulfonamides; Treatment Outcome | 2013 |
Retrospective analysis of the frequency of centrofacial telangiectasia in systemic sclerosis patients treated with bosentan or ilomedin.
Topics: Adult; Aged; Aged, 80 and over; Bosentan; Face; Female; Humans; Iloprost; Linear Models; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Sulfonamides; Telangiectasis | 2014 |
Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis.
Topics: Aged; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Iloprost; Laser-Doppler Flowmetry; Male; Microscopic Angioscopy; Middle Aged; Prospective Studies; Regional Blood Flow; Scleroderma, Systemic; Sulfonamides; Time Factors; Treatment Outcome; Vasodilator Agents | 2014 |
[Bosentan: a considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases].
Topics: Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Disease Progression; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Lupus Erythematosus, Systemic; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; Survival Rate; Treatment Outcome | 2014 |
Blood flow in the hands of a predefined homogeneous systemic sclerosis population: the presence of digital ulcers and the improvement with bosentan.
Topics: Adult; Aged; Analysis of Variance; Bosentan; Case-Control Studies; Drug Administration Schedule; Female; Hand; Humans; Male; Middle Aged; Prospective Studies; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2015 |
[Impact of bosentan therapy on stress-induced pulmonary hypertension in patients with systemic sclerosis].
Topics: Antihypertensive Agents; Biomarkers; Bosentan; Cardiac Catheterization; Echocardiography; Exercise; Exercise Test; Hemodynamics; Humans; Hypertension, Pulmonary; Middle Aged; Pulmonary Circulation; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2015 |
Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study.
Topics: Administration, Oral; Adult; Aged; Anemia; Arthralgia; Bosentan; Constipation; Diarrhea; Endothelin Receptor Antagonists; Female; Fingers; Herpes Zoster; Humans; Japan; Liver; Liver Function Tests; Male; Middle Aged; Prospective Studies; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome; Wound Healing | 2017 |
Effects of bosentan on the skin lesions: an observational study from a single center in Japan.
Topics: Adult; Aged; Antihypertensive Agents; Arteries; Bosentan; Connective Tissue Diseases; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Japan; Male; Middle Aged; Mixed Connective Tissue Disease; Prospective Studies; Pulmonary Artery; Raynaud Disease; Scleroderma, Systemic; Skin Diseases; Sulfonamides; Ulcer; Vasculitis | 2009 |
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Drug Administration Schedule; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Epidemiologic Methods; Epoprostenol; Exercise Test; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2010 |
Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Drug Administration Schedule; Endothelin Receptor Antagonists; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2010 |
Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial.
Topics: Aged; Bosentan; Endothelin Receptor Antagonists; Female; Fibrosis; Humans; Male; Middle Aged; Receptors, Endothelin; Scleroderma, Systemic; Skin Ulcer; Statistics as Topic; Sulfonamides; Treatment Outcome | 2010 |
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Comorbidity; Double-Blind Method; Exercise Test; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Prospective Studies; Quality of Life; Respiratory Function Tests; Scleroderma, Systemic; Sulfonamides; Survival Rate; Young Adult | 2010 |
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.
Topics: Adult; Bosentan; Double-Blind Method; Drug Administration Schedule; Endothelin Receptor Antagonists; Female; Fingers; Hand Dermatoses; Humans; Male; Middle Aged; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome; Wound Healing | 2011 |
Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Laser-Doppler Flowmetry; Male; Middle Aged; Raynaud Disease; Regional Blood Flow; Scleroderma, Systemic; Skin; Sulfonamides | 2010 |
Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Exercise Test; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Middle Aged; Pilot Projects; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2012 |
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
Topics: Activities of Daily Living; Administration, Oral; Antihypertensive Agents; Bosentan; Disability Evaluation; Double-Blind Method; Endothelin Receptor Antagonists; Female; Fingers; Health Status; Humans; Ischemia; Male; Middle Aged; Scleroderma, Systemic; Severity of Illness Index; Skin Ulcer; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2004 |
New hope for systemic sclerosis patients with digital ulcers.
Topics: Administration, Oral; Bosentan; Chemical and Drug Induced Liver Injury; Double-Blind Method; Endothelin Receptor Antagonists; Fingers; Foot Dermatoses; Hand Dermatoses; Humans; Scleroderma, Localized; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Toes; Treatment Outcome | 2005 |
The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Scleroderma, Systemic; Sulfonamides | 2005 |
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Connective Tissue Diseases; Endothelin A Receptor Antagonists; Epidemiologic Methods; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2006 |
Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Double-Blind Method; Endothelin Receptor Antagonists; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2006 |
Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
Topics: Adult; Antihypertensive Agents; Bosentan; Female; Humans; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2006 |
Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study.
Topics: Antihypertensive Agents; Blood Pressure; Bosentan; Coronary Circulation; Echocardiography, Doppler; Heart; Humans; Magnetic Resonance Imaging; Middle Aged; Myocardial Contraction; Scleroderma, Systemic; Sulfonamides | 2006 |
Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon.
Topics: Adult; Aged; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Male; Microcirculation; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2007 |
Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.
Topics: Administration, Oral; Adult; Aged; Bosentan; Brachial Artery; Dose-Response Relationship, Drug; E-Selectin; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Female; Humans; Hypertension, Pulmonary; Intercellular Adhesion Molecule-1; Male; Middle Aged; Prospective Studies; Regional Blood Flow; Scleroderma, Systemic; Sulfonamides; Ultrasonography; Vascular Endothelial Growth Factor A; Vasodilation | 2007 |
Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients.
Topics: Adolescent; Adult; Aged; Bosentan; Child; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Prospective Studies; Scleroderma, Systemic; Severity of Illness Index; Skin Ulcer; Sulfonamides; Treatment Outcome | 2008 |
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Topics: Antihypertensive Agents; Bosentan; Double-Blind Method; Endothelin Receptor Antagonists; Exercise; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2001 |
Bosentan therapy for pulmonary arterial hypertension.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Child; Double-Blind Method; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Liver; Lupus Erythematosus, Systemic; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; Walking | 2002 |
111 other study(ies) available for bosentan anhydrous and Sclerosis, Systemic
Article | Year |
---|---|
Treatment of Digital Ulcers and Reflux Oesophagitis in a Patient with Systemic Sclerosis: Increased Risk of Hepatotoxicity due to a Potential Drug-drug Interaction Between Bosentan and Vonoprazan.
Topics: Bosentan; Chemical and Drug Induced Liver Injury; Drug Interactions; Esophagitis, Peptic; Humans; Pharmaceutical Preparations; Pyrroles; Scleroderma, Systemic; Sulfonamides; Ulcer | 2021 |
Real-world effectiveness and safety of bosentan in Japanese patients with systemic sclerosis: A single-center retrospective study.
Topics: Bosentan; East Asian People; Humans; Retrospective Studies; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome | 2023 |
Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies.
Topics: Aged; Aged, 80 and over; Antibodies, Antinuclear; Autoantibodies; Bosentan; Cardiac Catheterization; Centrioles; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Female; Forced Expiratory Volume; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pyrimidines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents | 2020 |
Pulse Wave Velocity in Systemic Sclerosis: Potential Beneficial Effects of Bosentan on Forearm Arterial Stiffness? An Exploratory Study.
Topics: Blood Flow Velocity; Blood Pressure; Bosentan; Forearm; Humans; Pulse Wave Analysis; Scleroderma, Systemic; Vascular Stiffness | 2021 |
Novel Use of Bosentan for Postoperative Wound Healing of the Foot in Systemic Sclerosis.
Topics: Bosentan; Humans; Scleroderma, Systemic; Skin Ulcer; Wound Healing | 2021 |
Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Case-Control Studies; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Treatment Outcome; Ulcer | 2020 |
Effects of Bosentan in the Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: A Longitudinal, Multicenter, Uncontrolled Trial.
Topics: Bosentan; Fingers; Humans; Republic of Korea; Scleroderma, Systemic; Skin Ulcer; Ulcer | 2021 |
Improvement of peripheral artery disease with Sildenafil and Bosentan combined therapy in a patient with limited cutaneous systemic sclerosis: A case report.
Topics: Bosentan; Cardiovascular Agents; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Middle Aged; Peripheral Arterial Disease; Phosphodiesterase 5 Inhibitors; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides | 2017 |
Treatment of digital ulcers in systemic sclerosis: Case series study of thirteen patients and discussion on outcome.
Topics: Aged; Aged, 80 and over; Alprostadil; Bosentan; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Female; Fingers; Hand Dermatoses; Humans; Male; Middle Aged; Reproducibility of Results; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Time Factors; Treatment Outcome; Vasodilator Agents; Wound Healing | 2017 |
Assessment of treatment effects on digital ulcer and blood perfusion by laser speckle contrast analysis in a patient affected by systemic sclerosis.
Topics: Bosentan; Female; Fingers; Humans; Iloprost; Lasers; Methotrexate; Microcirculation; Microscopic Angioscopy; Middle Aged; para-Aminobenzoates; Raynaud Disease; Scattering, Radiation; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Tramadol; Treatment Outcome | 2017 |
Systemic sclerosis: severe pulmonary arterial hypertension and pericardial effusion at diagnosis.
Topics: Bosentan; Calcium Channel Blockers; Chest Pain; Diagnostic Errors; Diltiazem; Echocardiography; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Lung; Microscopic Angioscopy; Middle Aged; Pericardial Effusion; Pericarditis; Scleroderma, Systemic; Sulfonamides; Tomography, X-Ray Computed | 2018 |
A potential contribution of decreased galectin-7 expression in stratified epithelia to the development of cutaneous and oesophageal manifestations in systemic sclerosis.
Topics: Aged; Biomarkers; Bosentan; Endothelin Receptor Antagonists; Epithelium; Esophageal Diseases; Female; Galectins; Gene Expression Regulation; Humans; Keratinocytes; Male; Middle Aged; Pigmentation; Scleroderma, Systemic; Skin | 2019 |
Systemic capillary leak syndrome following bosentan treatment in a patient with systemic sclerosis.
Topics: Bosentan; Capillary Leak Syndrome; Endothelin Receptor Antagonists; Humans; Male; Middle Aged; Scleroderma, Systemic; Ultrasonography | 2019 |
Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility.
Topics: Acute Kidney Injury; Adult; Aged; Antihypertensive Agents; Bosentan; Case-Control Studies; Endothelin-1; Female; Humans; Hypertension; Male; Middle Aged; Pilot Projects; Receptor, Endothelin A; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2013 |
Endothelin receptor antagonism-based treatment for scleroderma renal crisis.
Topics: Adult; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Renal Insufficiency, Chronic; Scleroderma, Systemic; Sulfonamides | 2013 |
Bosentan and sildenafil: successful treatment in a sclerodermic patient with refractory ulcers.
Topics: Bosentan; Endothelin Receptor Antagonists; Female; Humans; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Remission Induction; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Sulfonamides; Sulfones | 2013 |
Pulmonary hypertension complicating connective tissue disease.
Topics: Antihypertensive Agents; Bosentan; Connective Tissue Diseases; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Lung Transplantation; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pyridazines; Scleroderma, Systemic; Sulfonamides | 2013 |
Improvement of plasma endothelin-1 and nitric oxide in patients with systemic sclerosis by bosentan therapy.
Topics: Aged; Antihypertensive Agents; Biomarkers; Bosentan; Endothelin-1; Humans; Hypertension, Pulmonary; Male; Middle Aged; Nitric Oxide; Prospective Studies; Scleroderma, Systemic; Severity of Illness Index; Sulfonamides; Time Factors; Treatment Outcome | 2014 |
In systemic sclerosis patients, bosentan is safe and effective for digital ulcer prevention and it seems to attenuate the development of pulmonary arterial hypertension.
Topics: Bosentan; Cardiovascular Agents; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Fingers; Humans; Hypertension, Pulmonary; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome | 2014 |
Management of digital vasculopathy in systemic sclerosis: benefits of multiple courses of endothelin-1 receptor antagonists.
Topics: Adult; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Vascular Diseases | 2014 |
Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.
Topics: Animals; Bosentan; Chromatin Immunoprecipitation; Collagen Type I; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Fibroblasts; Fibrosis; Humans; Immunoblotting; Mice; Phenotype; Proto-Oncogene Protein c-fli-1; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Scleroderma, Systemic; Signal Transduction; Skin; Sulfonamides | 2014 |
Use of bosentan for digital ulcers related to systemic sclerosis: a real-life retrospective French study of 89 patients treated since specific approval.
Topics: Adult; Aged; Bosentan; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelin Receptor Antagonists; Female; Fingers; France; Humans; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Smoking; Sulfonamides; Treatment Outcome; Ulcer | 2014 |
Screening for pulmonary arterial hypertension in patients with scleroderma--a New Zealand perspective.
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Echocardiography; Electrocardiography; Exercise Test; Humans; Hypertension, Pulmonary; Mass Screening; New Zealand; Physical Examination; Piperazines; Practice Patterns, Physicians'; Purines; Respiratory Function Tests; Rheumatology; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Surveys and Questionnaires; Vasodilator Agents | 2014 |
[Digital ulcers in systemic scleroderma].
Topics: Bosentan; Fingers; Hand Dermatoses; Humans; Iloprost; Phosphodiesterase 5 Inhibitors; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Wound Healing | 2014 |
Effects of macitentan and its active metabolite on cultured human systemic sclerosis and control skin fibroblasts.
Topics: Actins; Aged; Bosentan; Down-Regulation; Endothelin A Receptor Antagonists; Female; Fibroblasts; Humans; Male; Middle Aged; Pyrimidines; Scleroderma, Systemic; Skin; Sulfonamides | 2015 |
Endothelin receptor blockade ameliorates vascular fragility in endothelial cell-specific Fli-1-knockout mice by increasing Fli-1 DNA binding ability.
Topics: Actins; Animals; Bosentan; Capillary Permeability; Cell Line; Cells, Cultured; Chromatin Immunoprecipitation; Endothelial Cells; Endothelin Receptor Antagonists; Endothelin-1; Gene Expression; Humans; Immunoblotting; Immunohistochemistry; Mice; Mice, Knockout; Microvessels; Phosphorylation; Promoter Regions, Genetic; Protein Kinase C-delta; Proto-Oncogene Protein c-fli-1; Proto-Oncogene Proteins c-abl; Receptors, Endothelin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Scleroderma, Systemic; Sulfonamides; Vascular Diseases | 2015 |
Endothelin Receptors Expressed by Immune Cells Are Involved in Modulation of Inflammation and in Fibrosis: Relevance to the Pathogenesis of Systemic Sclerosis.
Topics: Anti-Inflammatory Agents; Bosentan; CD4-Positive T-Lymphocytes; Endothelin Receptor Antagonists; Endothelin-1; Female; Fibroblasts; Fibrosis; Humans; Inflammation; Interferon-gamma; Male; Middle Aged; Monocytes; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides | 2015 |
No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Blood Pressure; Bosentan; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Longitudinal Studies; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Recovery of Function; Scleroderma, Systemic; Sulfonamides; Time Factors; Treatment Outcome; Up-Regulation | 2017 |
Digital Ulcers, Systemic Sclerosis Sine Scleroderma and Paraneoplastic Phenomena Responding to Bosentan Therapy.
Topics: Adenocarcinoma; Aged; Biopsy, Fine-Needle; Bosentan; Diagnosis, Differential; Endothelin Receptor Antagonists; Female; Fingers; Humans; Lung Neoplasms; Neoplasm Staging; Paraneoplastic Syndromes; Pneumonectomy; Scleroderma, Systemic; Serologic Tests; Skin Ulcer; Sulfonamides; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Fli1 deficiency contributes to the downregulation of endothelial protein C receptor in systemic sclerosis: a possible role in prothrombotic conditions.
Topics: Adult; Aged; alpha-2-Antiplasmin; Analysis of Variance; Animals; Antigens, CD; Bleomycin; Bosentan; Case-Control Studies; Cells, Cultured; Down-Regulation; Endothelial Cells; Endothelial Protein C Receptor; Endothelin Receptor Antagonists; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Female; Fibrinolysin; Humans; Male; Mice; Microvessels; Middle Aged; Proto-Oncogene Protein c-fli-1; Receptors, Cell Surface; Scleroderma, Systemic; Sulfonamides; Thrombophilia | 2016 |
Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis.
Topics: Adult; Aged; Bosentan; Capillaries; Drug Therapy, Combination; Female; Humans; Male; Microscopic Angioscopy; Microvessels; Middle Aged; Nails; Raynaud Disease; Retrospective Studies; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2016 |
Digital ulcers in scleroderma patients: A retrospective observational study.
Topics: Adult; Bosentan; Female; Fingers; Humans; Iloprost; Leg; Male; Middle Aged; Retrospective Studies; Scleroderma, Localized; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome; Wound Healing | 2016 |
Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Capillaries; Drug Therapy, Combination; Female; Humans; Iloprost; Male; Microscopic Angioscopy; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2017 |
[Digital ulcers in systemic sclerosis : A retrospective heath service study analysing treatment with bosentan and other vasoactive therapies].
Topics: Adult; Bosentan; Female; Fingers; Germany; Guideline Adherence; Health Care Surveys; Humans; Male; Middle Aged; Practice Guidelines as Topic; Practice Patterns, Physicians'; Retrospective Studies; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome; Vasoconstrictor Agents; Young Adult | 2017 |
Bosentan for digital ulcers prevention does not worsen cardiopulmonary exercise test parameters in SSc patients with interstitial lung disease.
Topics: Adult; Bosentan; Disease Progression; Endothelin Receptor Antagonists; Exercise Test; Female; Fingers; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Receptor, Endothelin A; Respiratory Function Tests; Scleroderma, Systemic; Skin Ulcer; Statistics as Topic; Sulfonamides; Treatment Outcome | 2016 |
Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study.
Topics: Adult; Aged; Blotting, Western; Bosentan; Cell Transdifferentiation; Cells, Cultured; Coculture Techniques; Endothelial Cells; Endothelin Receptor Antagonists; Female; Fibroblasts; Humans; In Vitro Techniques; Middle Aged; Myofibroblasts; Pyrimidines; Real-Time Polymerase Chain Reaction; Scleroderma, Systemic; Sulfonamides | 2016 |
Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Capillaries; Drug Therapy, Combination; Female; Fingers; Humans; Iloprost; Male; Microscopic Angioscopy; Middle Aged; Prospective Studies; Regional Blood Flow; Scleroderma, Systemic; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2016 |
Controlling the digital ulcerative disease in systemic sclerosis is associated with improved hand function.
Topics: Adult; Aged; Bosentan; Disability Evaluation; Endothelin Receptor Antagonists; Female; Hand; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Scleroderma, Systemic; Severity of Illness Index; Skin Ulcer; Sulfonamides; Treatment Outcome | 2017 |
Non-healing ischaemic digital ulcer in a systemic sclerosis patient: a challenging clinical case.
Topics: Administration, Intravenous; Administration, Oral; Bosentan; Botulinum Toxins, Type A; Cross-Sectional Studies; Female; Fingers; Humans; Iloprost; Middle Aged; Phosphodiesterase 5 Inhibitors; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Sulfonamides; Treatment Outcome; Wound Healing | 2017 |
[Long-term therapy with endothelin-1 antagonist for pulmonary hypertension secondary to systemic sclerosis].
Topics: Antihypertensive Agents; Bosentan; Endothelin-1; Fatal Outcome; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prognosis; Scleroderma, Systemic; Sulfonamides | 2008 |
N-terminal pro-brain natriuretic peptide in systemic sclerosis related pulmonary arterial hypertension under bosentan treatment.
Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Models, Biological; Natriuretic Peptide, Brain; Peptide Fragments; Scleroderma, Systemic; Sulfonamides | 2009 |
Successful treatment with bosentan of non-digital skin ulcers in severe scleroderma.
Topics: Bosentan; Endothelin Receptor Antagonists; Female; Humans; Leg Ulcer; Middle Aged; Scleroderma, Systemic; Sulfonamides | 2008 |
Role of endogenous endothelin in endothelial dysfunction in murine model of systemic sclerosis: tight skin mice 1.
Topics: Acetylcholine; Animals; Bosentan; Cyclooxygenase Inhibitors; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Mesenteric Arteries; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Myocardium; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Prostaglandins; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Vasodilation; Vasodilator Agents | 2008 |
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Topics: Bosentan; Cohort Studies; Comorbidity; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Lung Diseases, Interstitial; Male; Maryland; Middle Aged; Piperazines; Prognosis; Proportional Hazards Models; Purines; Receptors, Endothelin; Scleroderma, Diffuse; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Vasodilator Agents | 2009 |
Delayed hypersensitivity to bosentan.
Topics: Adult; Antihypertensive Agents; Betamethasone; Bosentan; Exanthema; Female; Glucocorticoids; Humans; Hypersensitivity, Delayed; Hypertension, Pulmonary; Lymphocyte Activation; Scleroderma, Systemic; Skin Tests; Sulfonamides | 2009 |
Severe hepatotoxicity in a patient on bosentan upon addition of methotrexate: reversible with resumption of methotrexate without bosentan.
Topics: Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Dermatologic Agents; Drug Interactions; Female; Humans; Hypertension, Pulmonary; Methotrexate; Middle Aged; Polypharmacy; Scleroderma, Systemic; Sulfonamides | 2009 |
Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Cytokines; Endothelin-1; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Interleukin-12; Male; Middle Aged; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides | 2009 |
Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study.
Topics: Aged; Antihypertensive Agents; Biopsy; Bosentan; Female; Fingers; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Scleroderma, Systemic; Skin; Skin Ulcer; Sulfonamides; Treatment Outcome | 2009 |
Graves' disease associated with primary systemic sclerosis.
Topics: Azathioprine; Bosentan; Cyclophosphamide; Drug Therapy, Combination; Female; Glucocorticoids; Graves Disease; Humans; Hypertension, Pulmonary; Immunoglobulins, Intravenous; Immunosuppressive Agents; Methotrexate; Middle Aged; Mycophenolic Acid; Proteinuria; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2009 |
Liver impairment after concomitant administration of bosentan and clarithromycin in systemic sclerosis.
Topics: Aged; Anti-Bacterial Agents; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Clarithromycin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fingers; Humans; Hypertension, Pulmonary; Liver Function Tests; Middle Aged; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2010 |
Bosentan-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.
Topics: Aged; Anti-Ulcer Agents; Bosentan; Drug Hypersensitivity; Eosinophilia; Exanthema; Female; Fever; Humans; Scleroderma, Systemic; Sulfonamides; Syndrome | 2010 |
A higher degree of criticism about the effectiveness of bosentan for digital ulcers in scleroderma patients, as for interstitial disease, is also necessary: comment on the article by Seibold et al.
Topics: Antihypertensive Agents; Bosentan; Endothelins; Fingers; Humans; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2010 |
Bosentan ameliorated exercise-induced pulmonary arterial hypertension complicated with systemic sclerosis.
Topics: Bosentan; Exercise; Exercise Test; Female; Humans; Hypertension, Pulmonary; Middle Aged; Scleroderma, Systemic; Sulfonamides | 2010 |
[Efficacy of combination therapy with bosentan and sildenafil for refractory pulmonary arterial hypertension associated with fibrotic lung in systemic sclerosis].
Topics: Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Middle Aged; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2010 |
Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma.
Topics: Adult; Aged; Biopsy; Bosentan; Case-Control Studies; CD4-Positive T-Lymphocytes; Dermatitis; Dermatologic Agents; Endothelin A Receptor Antagonists; Female; Forkhead Transcription Factors; Humans; Immune Tolerance; Male; Middle Aged; Scleroderma, Localized; Scleroderma, Systemic; Skin; Sulfonamides; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory | 2011 |
Connective tissue diseases: Treatment of digital ulcers in systemic sclerosis.
Topics: Bosentan; Diarrhea; Endothelin Receptor Antagonists; Fingers; Hand; Humans; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Transaminases; Treatment Outcome | 2011 |
[A complication of coronary angiography in a female patient with systemic sclerosis].
Topics: Aged; Antihypertensive Agents; Arterial Occlusive Diseases; Bosentan; Coronary Angiography; Female; Humans; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2011 |
Bosentan improves systemic sclerosis-related peripheral circulation insufficiency.
Topics: Adult; Aged; Blood Circulation; Bosentan; Female; Humans; Middle Aged; Pain Measurement; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2011 |
Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis.
Topics: Bosentan; Canada; Epoprostenol; Europe; Health Surveys; Humans; Hypertension, Pulmonary; Iloprost; Methotrexate; North America; Practice Guidelines as Topic; Scleroderma, Systemic; Skin Diseases; Societies, Medical; Sulfonamides; Treatment Outcome; Vascular Diseases | 2011 |
Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study.
Topics: Antihypertensive Agents; Bosentan; Cohort Studies; Humans; Hypertension; Ischemia; Randomized Controlled Trials as Topic; Retrospective Studies; Scleroderma, Systemic; Skin Ulcer; Spain; Sulfonamides; Treatment Outcome | 2011 |
Chronic leg ulceration as the presenting feature of diffuse systemic sclerosis in childhood.
Topics: Adolescent; Bosentan; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Leg Ulcer; Nifedipine; Scleroderma, Systemic; Sulfonamides; Vasodilator Agents | 2011 |
Successful treatment with bosentan for pulmonary hypertension and reduced peripheral circulation in juvenile systemic sclerosis.
Topics: Antihypertensive Agents; Bosentan; Child; Dose-Response Relationship, Drug; Echocardiography; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Pulmonary Wedge Pressure; Scleroderma, Systemic; Sulfonamides; Thermography; Vascular Resistance | 2011 |
Effect of a sequential therapy of bosentan and iloprost versus a monotherapy with bosentan in the treatment of scleroderma related digital ulcers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bosentan; Drug Therapy, Combination; Female; Fingers; Humans; Iloprost; Infusions, Intravenous; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Time Factors; Treatment Outcome; Vasodilator Agents; Wound Healing; Young Adult | 2011 |
Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis.
Topics: Bosentan; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Fingers; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Sulfonamides; Sulfones | 2011 |
Effects of bosentan on nondigital ulcers in patients with systemic sclerosis.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Dermatologic Agents; Female; Foot Ulcer; Humans; Hypertension, Pulmonary; Middle Aged; Off-Label Use; Scleroderma, Systemic; Sulfonamides; Treatment Outcome; Wound Healing | 2012 |
Bosentan is effective against digital ulcerations and hyperkeratosis in systemic sclerosis.
Topics: Antihypertensive Agents; Bosentan; Female; Hand Dermatoses; Humans; Keratosis; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2011 |
Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Cyclophosphamide; Female; Humans; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Prospective Studies; Respiratory Function Tests; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2011 |
Bosentan for digital ulcers in patients with systemic sclerosis.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Female; Hand Dermatoses; Humans; Male; Middle Aged; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome; Young Adult | 2012 |
Nonoperative treatment of digital ischemia in systemic sclerosis.
Topics: Bosentan; Botulinum Toxins, Type A; Calcium Channel Blockers; Education, Medical, Continuing; Endothelin Receptor Antagonists; Evidence-Based Medicine; Female; Fingers; Humans; Iloprost; Ischemia; Life Style; Middle Aged; Orthopedics; Phosphodiesterase 5 Inhibitors; Prostaglandins; Randomized Controlled Trials as Topic; Raynaud Disease; Scleroderma, Systemic; Sulfonamides; Vascular Resistance; Vasodilator Agents | 2012 |
Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; Methylprednisolone; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2012 |
Bosentan fosters microvascular de-remodelling in systemic sclerosis.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Capillaries; Female; Humans; Male; Microscopic Angioscopy; Microvessels; Middle Aged; Nails; Scleroderma, Systemic; Sulfonamides; Treatment Outcome; Young Adult | 2012 |
Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Capillaries; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Iloprost; Male; Microscopic Angioscopy; Microvessels; Middle Aged; Nails; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2013 |
Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Liver; Liver Function Tests; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Safety-Based Drug Withdrawals; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2012 |
Endothelin receptor antagonists: effects on extracellular matrix synthesis in primary cultures of skin fibroblasts from systemic sclerosis patients.
Topics: Aged; Bosentan; Cells, Cultured; Collagen Type I; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Extracellular Matrix Proteins; Female; Fibrillin-1; Fibrillins; Fibroblasts; Fibronectins; Fibrosis; Humans; Isoxazoles; Microfilament Proteins; Middle Aged; Primary Cell Culture; Scleroderma, Systemic; Sulfonamides; Thiophenes | 2012 |
Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study.
Topics: Aged; Antihypertensive Agents; Bosentan; Case-Control Studies; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Fingers; Humans; Hypertension, Pulmonary; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Time Factors; Treatment Outcome; Vascular Diseases | 2013 |
Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan.
Topics: Bosentan; Endothelin Receptor Antagonists; Fingers; Humans; Hypertension, Pulmonary; Ischemia; Male; Middle Aged; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2003 |
Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Lung; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2003 |
Scleroderma: a treatable disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bosentan; Humans; Pulmonary Fibrosis; Scleroderma, Systemic; Sulfonamides | 2003 |
Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD.
Topics: Adult; Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Kidney Failure, Chronic; Scleroderma, Systemic; Sulfonamides | 2004 |
Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis.
Topics: Adult; Bosentan; Female; Humans; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2004 |
[Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience].
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Physical Endurance; Pilot Projects; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2004 |
Resolution of severe digital ulceration during a course of Bosentan therapy.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Fingers; Humans; Hypertension, Pulmonary; Male; Middle Aged; Scleroderma, Systemic; Skin Ulcer; Sulfonamides | 2005 |
Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Exercise Tolerance; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Recovery of Function; Scleroderma, Systemic; Sulfonamides; Survival Analysis; Time Factors; Treatment Outcome | 2005 |
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.
Topics: Antihypertensive Agents; Bosentan; Epoprostenol; Exercise Test; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prognosis; Prostaglandins; Scleroderma, Systemic; Sulfonamides; Survival Analysis; Vasodilator Agents | 2006 |
Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade.
Topics: Aged; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Pulmonary Wedge Pressure; Receptors, Endothelin; Sarcoidosis, Pulmonary; Scleroderma, Systemic; Sulfonamides; Thromboembolism | 2005 |
Bosentan in pulmonary arterial hypertension secondary to scleroderma.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Respiratory Function Tests; Retrospective Studies; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2006 |
[Endothelin receptor antagonism in routine clinical care].
Topics: Bosentan; Controlled Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Prognosis; Scleroderma, Systemic; Sulfonamides; Survival Analysis | 2005 |
Treatment of severe Raynaud's phenomenon with bosentan in a patient with systemic sclerosis.
Topics: Adult; Bosentan; Female; Fingers; Gangrene; Humans; Raynaud Disease; Scleroderma, Systemic; Sulfonamides | 2006 |
Bosentan may induce arthritis flare in patients with scleroderma concomitantly treated with methotrexate.
Topics: Antihypertensive Agents; Arthritis; Bosentan; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Methotrexate; Middle Aged; Scleroderma, Systemic; Sulfonamides | 2006 |
[Bosentan for treatment of active digital ulcers in patients with systemic sclerosis].
Topics: Adult; Aged; Antibodies, Antinuclear; Bosentan; Endothelin-1; Female; Fingers; Follow-Up Studies; Humans; Ischemia; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Time Factors; Treatment Outcome | 2006 |
Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy.
Topics: Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Middle Aged; Sarcoidosis, Pulmonary; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Tomography, X-Ray Computed | 2006 |
Drug eruption due to bosentan in a patient with systemic sclerosis.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Bosentan; Drug Eruptions; Endothelin Receptor Antagonists; Eosinophilia; Female; Humans; Hypertension, Pulmonary; Middle Aged; Prednisolone; Scleroderma, Systemic; Sulfonamides | 2006 |
Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Endothelin Receptor Antagonists; Exercise Test; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; Middle Aged; Prospective Studies; Pulmonary Fibrosis; Scleroderma, Systemic; Sulfonamides; Walking | 2006 |
Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases.
Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Connective Tissue Diseases; Exercise Test; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Mixed Connective Tissue Disease; Myositis; Prospective Studies; Scleroderma, Systemic; Sulfonamides; Treatment Outcome; Ventricular Dysfunction, Right; Walking | 2006 |
Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPs.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinases; Treatment Outcome | 2006 |
Bosentan improves functional class, pulmonary artery systolic pressure, and DLCO in scleroderma patients with pulmonary hypertension: a possible synergy with iloprost.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Respiratory Function Tests; Retrospective Studies; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2006 |
Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Exercise Test; Female; Humans; Hypertension, Pulmonary; Lung Volume Measurements; Male; Middle Aged; Piperazines; Pulmonary Wedge Pressure; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2007 |
[Systemic sclerosis: paths into the future].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Forecasting; Humans; Phosphodiesterase Inhibitors; Piperazines; Prognosis; Prostaglandins I; Purines; Quality of Life; Research; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2006 |
Bosentan as a rescue therapy in scleroderma refractory digital ulcers.
Topics: Adult; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome | 2007 |
Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Bosentan; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2007 |
[Treatment of a leg ulcer with bosentan in a female patient with progressive systemic scleroderma].
Topics: Administration, Oral; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Middle Aged; Scleroderma, Systemic; Sulfonamides; Varicose Ulcer | 2007 |
[Digital necrosis in scleroderma].
Topics: Adult; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Iloprost; Necrosis; Platelet Aggregation Inhibitors; Recurrence; Scleroderma, Systemic; Sulfonamides; Vasodilator Agents | 2007 |
Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts.
Topics: Biopsy; Bosentan; Cell Adhesion; Cells, Cultured; Collagen Type I; Connective Tissue Growth Factor; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Fibroblasts; Fibrosis; Gene Expression Profiling; Gene Expression Regulation; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Lung; Receptor, Endothelin A; Receptor, Endothelin B; RNA, Messenger; Scleroderma, Systemic; Signal Transduction; Sulfonamides | 2007 |
Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Female; Humans; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2007 |
[The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Injections, Intravenous; Phosphodiesterase Inhibitors; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2007 |
Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Antinuclear; Antihypertensive Agents; Autoantibodies; Bosentan; Case-Control Studies; CD3 Complex; Cell Adhesion Molecules; Centromere; Endothelin-1; Female; Humans; Hypertension, Pulmonary; Integrin alpha4beta1; L-Selectin; Lymphocyte Function-Associated Antigen-1; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; T-Lymphocytes | 2008 |
N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH.
Topics: Adult; Aged; Bosentan; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Scleroderma, Systemic; Sulfonamides | 2008 |
N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Bosentan; Exercise Test; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Scleroderma, Systemic; Sulfonamides | 2008 |
Diagnosis of pulmonary arterial hypertension in a patient with systemic sclerosis.
Topics: Adult; Antihypertensive Agents; Bosentan; Dyspnea; Echocardiography; Exercise Test; Female; Humans; Hypertension, Pulmonary; Natriuretic Peptide, Brain; Respiratory Function Tests; Scleroderma, Systemic; Sulfonamides | 2008 |
[Digital ulcers in systemic sclerosis].
Topics: Bosentan; Fingers; Humans; Iloprost; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Vasodilator Agents | 2008 |
Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach.
Topics: Bosentan; Drug Therapy, Combination; Electrocardiography; Female; Humans; Hypertension, Pulmonary; Iloprost; Middle Aged; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2008 |